Cache Advisors LLC Makes New $534,000 Investment in Penumbra, Inc. (NYSE:PEN)

Cache Advisors LLC acquired a new stake in Penumbra, Inc. (NYSE:PEN - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 2,250 shares of the company's stock, valued at approximately $534,000.

A number of other institutional investors also recently added to or reduced their stakes in PEN. Quadrant Capital Group LLC increased its holdings in Penumbra by 6.6% in the fourth quarter. Quadrant Capital Group LLC now owns 632 shares of the company's stock valued at $150,000 after buying an additional 39 shares in the last quarter. Baker Avenue Asset Management LP raised its stake in shares of Penumbra by 1.6% during the 4th quarter. Baker Avenue Asset Management LP now owns 3,330 shares of the company's stock worth $791,000 after buying an additional 53 shares during the last quarter. Pacer Advisors Inc. raised its stake in shares of Penumbra by 1.0% during the 4th quarter. Pacer Advisors Inc. now owns 5,721 shares of the company's stock worth $1,359,000 after buying an additional 57 shares during the last quarter. CIBC Asset Management Inc boosted its position in shares of Penumbra by 5.4% in the 4th quarter. CIBC Asset Management Inc now owns 1,183 shares of the company's stock worth $281,000 after buying an additional 61 shares in the last quarter. Finally, Corient Private Wealth LLC grew its stake in Penumbra by 3.7% in the 4th quarter. Corient Private Wealth LLC now owns 1,695 shares of the company's stock valued at $403,000 after acquiring an additional 61 shares during the last quarter. Hedge funds and other institutional investors own 88.88% of the company's stock.

Penumbra Stock Performance

PEN traded down $8.55 during trading hours on Wednesday, hitting $264.08. The company's stock had a trading volume of 752,148 shares, compared to its average volume of 444,549. The company has a 50-day simple moving average of $279.26 and a 200 day simple moving average of $265.67. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $10.23 billion, a PE ratio of 776.71, a PEG ratio of 2.83 and a beta of 0.53. Penumbra, Inc. has a fifty-two week low of $148.00 and a fifty-two week high of $310.00.

Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, beating analysts' consensus estimates of $0.66 by $0.17. The company had revenue of $324.14 million for the quarter, compared to analyst estimates of $315.72 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company's quarterly revenue was up 16.3% compared to the same quarter last year. During the same period last year, the company earned $0.41 earnings per share. As a group, sell-side analysts expect that Penumbra, Inc. will post 3.67 EPS for the current year.

Insider Transactions at Penumbra

In other news, Director Arani Bose sold 12,000 shares of the business's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $283.77, for a total value of $3,405,240.00. Following the sale, the director now owns 314,819 shares of the company's stock, valued at approximately $89,336,187.63. The trade was a 3.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Adam Elsesser sold 61,600 shares of Penumbra stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $283.59, for a total transaction of $17,469,144.00. Following the completion of the transaction, the chief executive officer now owns 16,376 shares in the company, valued at approximately $4,644,069.84. This trade represents a 79.00% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 176,696 shares of company stock valued at $50,207,745. Company insiders own 5.00% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. BTIG Research reiterated a "buy" rating on shares of Penumbra in a research report on Thursday, April 24th. Stifel Nicolaus set a $318.00 target price on Penumbra and gave the company a "buy" rating in a report on Thursday, April 24th. UBS Group reissued a "buy" rating and issued a $330.00 price target (up from $320.00) on shares of Penumbra in a report on Thursday, April 24th. Truist Financial increased their price objective on Penumbra from $315.00 to $330.00 and gave the company a "buy" rating in a research note on Thursday, April 24th. Finally, Wells Fargo & Company boosted their target price on shares of Penumbra from $305.00 to $315.00 and gave the company an "overweight" rating in a research note on Thursday, April 24th. Three investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $302.40.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.